

**CONSENT &  
AUTHORIZATION**

**IRB Protocol Number:** Pending  
**IRB Approval date:** TBD  
**Version:** 11/5/2021

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13

Study Title	Expanding use of continuous glucose monitoring beyond COVID in critical care: Impact on nurse work patterns and patient outcomes
NCT Number	N/A
Document Description	Informed Consent Form

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

## **The Ohio State University Combined Consent to Participate in Research and HIPAA Research Authorization**

**Study Title: Expanding use of continuous glucose monitoring beyond  
COVID in critical care: Impact on nurse work patterns and patient  
outcomes**

**Principal Investigator: Eileen Faulds, PhD, MS, RN, FNP-BC, CDCES**

**Sponsor: Dexcom, Inc.**

36  
37     • **This is a consent form for research participation.** It contains important information  
38     about this study and what to expect if you decide to participate. Please consider the  
39     information carefully. Feel free to discuss the study with your friends and family and  
40     to ask questions before making your decision whether or not to participate.  
41  
42     • **Your participation is voluntary.** You may refuse to participate in this study. If you  
43     decide to take part in the study, you may leave the study at any time. No matter what  
44     decision you make, there will be no penalty to you and you will not lose any of your  
45     usual benefits. Your decision will not affect your future relationship with The Ohio  
46     State University. If you are a student or employee at Ohio State, your decision will  
not affect your grades or employment status.  
47  
48     • **You may or may not benefit as a result of participating in this study.** Also, as  
49     explained below, your participation may result in unintended or harmful effects for  
you that may be minor or may be serious depending on the nature of the research.  
50  
51     • **You will be provided with any new information that develops during the study  
52     that may affect your decision whether or not to continue to participate.** If you  
53     decide to participate, you will be asked to sign this form and will receive a copy of the  
54     form. You are being asked to consider participating in this study for the reasons  
explained below.  
55

### **Key Information About This Study**

56  
57     The following is a short summary to help you decide whether or not to be a part of this study.  
58     More detailed information is listed later in this form.  
59

60     • This study is to determine if it is safe, effective, and practical to use continuous blood  
61     glucose monitoring (CGM) devices in hospital settings.

- These devices are commonly used outside the hospital for people with diabetes but their use inside the hospital has not been approved and is therefore investigational.
- Individuals in the intensive care unit are very ill and we have not fully investigated how illness could affect device accuracy.
- The use of these monitors could reduce the number of finger stick blood sugar checks for patients, avoid low blood sugars and give more accurate insulin dosing for patients.
- Using these monitors could also make the workload of hospital staff more manageable, resulting in better overall care for all patients.
- You would not need to do anything other than agree to wear the monitor while in the hospital.

## 1. Why is this study being done?

This study is to determine if the use of continuous glucose monitors (CGM) in hospital settings will benefit patients and/or staff and can be safely used as a replacement for some traditional fingerstick glucose testing.

## 2. How many people will take part in this study?

There will be approximately 100 patients who take part in this study.

## 3. What will happen if I take part in this study?

If you decide to take part in this study, you will be asked to wear a continuous glucose monitor (CGM) while you are in the Intensive Care Unit. The monitor will be placed on your arm by hospital staff. The monitor is replaced every 10 days. If you are still in the hospital after 10 days, the CGM may be replaced. You will be given finger stick blood sugar tests every 4 hours to test the accuracy of the monitors. Finger stick monitoring will be done more frequently if your clinical condition changes and if you were to become more severely ill, the CGM would remain in place to collect information but would not be used to monitor your glucose. If you are not on CGM you would have your glucose checked by a fingerstick 4 to 24 times a day depending on what kind of insulin you are on.

If you choose to be in this study, then some of your medical information will be taken from your electronic medical record to compare to patients who did not wear the continuous monitor.

## 4. How long will I be in the study?

You will continue to wear the monitor as long as you are in the Intensive Care Unit (ICU).

## 5. Can I stop being in the study?

You may leave the study at any time. If you decide to stop participating in the study, there will be no penalty to you, and you will not lose any benefits to which you are

105 otherwise entitled. Your decision will not affect your future relationship with The  
106 Ohio State University.

108 **6. What risks, side effects or discomforts can I expect from being in the study?**

109 There is a risk that the CGM system may fail to detect either high glucose  
110 (hyperglycemia) or low glucose (hypoglycemia). Failure to accurately detect a high or  
111 low glucose could result in inappropriate insulin dosing or failure to give insulin and  
112 could lead to injury or even death. We will reduce this risk by continuing to perform  
113 finger stick tests to check the accuracy of the CGM system throughout the study.  
114 There may be some discomfort or pain when the continuous monitor is attached to  
115 your skin. There is very minimal risk of infection during installation. The finger stick  
116 tests are used to protect against the monitor being inaccurate or failing.

118 **7. What benefits can I expect from being in the study?**

119 There will be no direct benefits to you if you participate in the study.

121 **8. What other choices do I have if I do not take part in the study?**

122 You may choose not to participate without penalty or loss of benefits to which you are  
123 otherwise entitled.

125 **9. What are the costs of taking part in this study?**

126 There are no costs to you for taking part in this study.

128 **11. What happens if I am injured because I took part in this study?**

129 If you suffer an injury from participating in this study, you should notify the  
130 researcher or study doctor immediately, who will determine if you should obtain  
131 medical treatment at The Ohio State University Wexner Medical Center.

133 The cost for this treatment will be billed to you or your medical or hospital insurance.  
134 The Ohio State University has no funds set aside for the payment of health care  
135 expenses for this study.

137 **12. What are my rights if I take part in this study?**

138 If you choose to participate in the study, you may discontinue participation at any time  
139 without penalty or loss of benefits. By signing this form, you do not give up any  
140 personal legal rights you may have as a participant in this study.

142 You will be provided with any new information that develops during the course of the  
143 research that may affect your decision whether or not to continue participation in the  
144 study.

146 You may refuse to participate in this study without penalty or loss of benefits to which  
147 you are otherwise entitled.

149 An Institutional Review Board responsible for human subjects research at The Ohio  
150 State University reviewed this research project and found it to be acceptable,  
151 according to applicable state and federal regulations and University policies designed  
152 to protect the rights and welfare of research participants.  
153

154 **13. Will my de-identified information be used or shared for future research?**

155 Yes, it/they may be used or shared with other researchers without your additional  
156 informed consent.  
157

158 **Future Research Use:**

159 With your permission, Dexcom, the study funder, would like to store your de-  
160 identifiable information for future research purposes, and as part of such future research  
161 purposes, your de-identifiable information may be disclosed to people or entities not  
162 listed above, such as researchers not involved with this study, government agencies,  
163 research foundations, or pharmaceutical or device companies sponsoring future  
164 research.  
165  
166  
167

168 **You do not have to agree to use of your de-identified data for future research in order to  
169 be in this study, and your decision will not affect the care you receive at The Ohio  
170 State University.**

171 I agree to allow my de-identified data to be stored and used for future research as  
172 described above: (initial)  
173

174         YES  NO  
175  
176

177 **14. Will my study-related information be kept confidential?**

178 Efforts will be made to keep your study-related information confidential. However,  
179 there may be circumstances where this information must be released. For example,  
180 personal information regarding your participation in this study may be disclosed if  
181 required by state law.  
182

183 Also, your records may be reviewed by the following groups (as applicable to the  
184 research):  
185

- 186 • Office for Human Research Protections or other federal, state, or international  
187 regulatory agencies;
- 188 • U.S. Food and Drug Administration;
- 189 • The Ohio State University Institutional Review Board or Office of Responsible  
190 Research Practices;
- 191 • The sponsor supporting the study, their agents or study monitors; and
- 192 • Your insurance company (if charges are billed to insurance).

193  
194 A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as  
195 required by U.S. law. This website will not include information that can identify you. At  
196 most, the website will include a summary of the results. You can search the website at  
197 any time.

198

## 199 **15. HIPAA AUTHORIZATION TO USE AND DISCLOSE INFORMATION FOR** 200 **RESEARCH PURPOSES**

201

### **I. What information may be used and given to others?**

202

- 203 • Past and present medical records;
- 204 • Research records;
- 205 • Records about phone calls made as part of this research;
- 206 • Information that includes personal identifiers, such as your name, or a number  
207 associated with you as an individual;
- 208 • Information gathered for this research about laboratory, x-ray, and other test  
209 results;
- 210 • Records about the study device

211

### **II. Who may use and give out information about you?**

212 Researchers and study staff.

213

### **III. Who might get this information?**

214

- 215 • The sponsor of this research. "Sponsor" means any persons or companies that are:
  - 216 • working for or with the sponsor; or
  - 217 • owned by the sponsor.
- 218 • Authorized Ohio State University staff not involved in the study may be aware that  
219 you are participating in a research study and have access to your information;
- 220 • If this study is related to your medical care, your study-related information may be  
221 placed in your permanent hospital, clinic, or physician's office record;
- 222 • Others: Dexcom, Inc.

223

### **IV. Your information may be given to:**

224

- 225 • The U.S. Food and Drug Administration (FDA), Department of Health and Human  
226 Services (DHHS) agencies, and other federal and state entities;
- 227 • Governmental agencies in other countries;
- 228 • Governmental agencies to whom certain diseases (reportable diseases) must be  
229 reported; and
- 230 • The Ohio State University units involved in managing and approving the research  
231 study including the Office of Research and the Office of Responsible Research  
232 Practices.

236 **V. Why will this information be used and/or given to others?**

237 • To do the research;  
238 • To study the results; and  
239 • To make sure that the research was done right.

241 **VI. When will my permission end?**

242 There is no date at which your permission ends. Your information will be used  
243 indefinitely. This is because the information used and created during the study may be  
244 analyzed for many years, and it is not possible to know when this will be complete.

246 **VII. May I withdraw or revoke (cancel) my permission?**

247 Yes. Your authorization will be good for the time period indicated above unless you  
248 change your mind and revoke it in writing. You may withdraw or take away your  
249 permission to use and disclose your health information at any time. You do this by  
250 sending written notice to the researchers. If you withdraw your permission, you will  
251 not be able to stay in this study. When you withdraw your permission, no new health  
252 information identifying you will be gathered after that date. Information that has  
253 already been gathered may still be used and given to others.

255 **VIII. What if I decide not to give permission to use and give out my health  
256 information?**

257 Then you will not be able to be in this research study and receive research-related  
258 treatment. However, if you are being treated as a patient here, you will still be able to  
259 receive care.

261 **IX. Is my health information protected after it has been given to others?**

262 There is a risk that your information will be given to others without your permission.  
263 Any information that is shared may no longer be protected by federal privacy rules.

265 **X. May I review or copy my information?**

266 Signing this authorization also means that you may not be able to see or copy your  
267 study-related information until the study is completed.

270 **16. Who can answer my questions about the study?**

271 For study questions, concerns, or complaints, to withdraw consent and HIPAA  
272 authorization, or if you feel you have been harmed as a result of study participation, you  
273 may contact Eileen Faulds at (614) 293-0477 or [Eileen.faulds@osumc.edu](mailto:Eileen.faulds@osumc.edu).

275 For questions related to your privacy rights under HIPAA or related to this research  
276 authorization, please contact Mary Beth Happ at (614) 292-8336 or [happ.3@osu.edu](mailto:happ.3@osu.edu).

278 For questions about your rights as a participant in this study or to discuss other study-  
279 related concerns or complaints with someone who is not part of the research team, you  
280 may contact the Office of Responsible Research Practices at 1-800-678-6251.  
281  
282 If you are injured as a result of participating in this study or for questions about a study-  
283 related injury, you may contact Eileen Faulds at (614) 293-0477 or  
284 [Eileen.faulds@osumc.edu](mailto:Eileen.faulds@osumc.edu).  
285  
286  
287

288 **Signing the consent form**

289  
290 I have read (or someone has read to me) this form and I am aware that I am being asked to  
291 participate in a research study. I have had the opportunity to ask questions and have had them  
292 answered to my satisfaction. I voluntarily agree to participate in this study.

293  
294 I am not giving up any legal rights by signing this form. I will be given a copy of this  
295 combined consent and HIPAA research authorization form.

296

---

Printed name of participant

---

Signature of participant

AM/PM

---

Date and time

---

Printed name of person authorized to consent for  
participant (when applicable)

---

Signature of person authorized to consent for participant  
(when applicable)

AM/PM

---

Relationship to the participant

---

Date and time

297

298

**Investigator/Research Staff**

300  
301 I have explained the research to the participant or his/her representative before requesting the  
302 signature(s) above. There are no blanks in this document. A copy of this form has been given  
303 to the participant or his/her representative.

304

---

Printed name of person obtaining consent

---

Signature of person obtaining consent

AM/PM

---

Date and time

305

306

**Witness(es) - May be left blank if not required by the IRB**

307

---

Printed name of witness

---

Signature of witness

AM/PM

---

Date and time

---

Printed name of witness

---

Signature of witness

AM/PM

---

Date and time

308